<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36792010</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1538-7836</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of thrombosis and haemostasis : JTH</Title><ISOAbbreviation>J Thromb Haemost</ISOAbbreviation></Journal><ArticleTitle>Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients.</ArticleTitle><Pagination><StartPage>1258</StartPage><EndPage>1265</EndPage><MedlinePgn>1258-1265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jtha.2023.02.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1538-7836(23)00146-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">The prevention of catastrophic antiphospholipid syndrome (CAPS), a rare complication of antiphospholipid syndrome (APS), is a major goal.</AbstractText><AbstractText Label="OBJECTIVES">We analyzed its precipitating factors, focusing on anticoagulation immediately before CAPS episodes.</AbstractText><AbstractText Label="METHODS">We retrospectively analyzed patients in the French multicenter APS/systemic lupus erythematosus database with at least 1 CAPS episode. Then we compared each patient with known APS before CAPS with 2 patients with non-CAPS APS matched for age, sex, center, and APS phenotype.</AbstractText><AbstractText Label="RESULTS">We included 112 patients with CAPS (70% women; mean age, 43&#xa0;&#xb1; 15 years). At least 1 standard precipitating factor of CAPS was observed for 67 patients (64%), which were mainly infections (n&#xa0;= 28, 27%), pregnancy (n&#xa0;= 23, 22%), and surgery (n&#xa0;= 16, 15%). Before the CAPS episode, 67 (60%) patients already had a diagnosis of APS. Of the 61 treated with anticoagulants, 32 (48%) received vitamin K antagonists (VKAs), 23 (34%) heparin, and 2 (3%) a direct oral anticoagulant. They were less likely than their matched patients with APS without CAPS to receive VKA (48% vs 66%, p&#xa0;= .001). Among those treated with VKA, 72% had a subtherapeutic international normalized ratio (ie, &lt;2) versus 28% in patients with APS without CAPS (p&#xa0;&lt; .001). Finally, excluding pregnant patients (n&#xa0;= 14) for whom we could not differentiate the effect of treatment from that of pregnancy, we were left with 47 cases, 32 (68%) of whom had recently begun a direct oral anticoagulant, planned bridging therapy, or had VKA treatment with international normalized ratio &lt;2.</AbstractText><AbstractText Label="CONCLUSION">These results strongly suggest that suboptimal anticoagulation management can trigger CAPS in patients with thrombotic APS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stammler</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Yann</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yelnik</LastName><ForeName>C&#xe9;cile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Service de M&#xe9;decine Interne et d'Immunologie Clinique, Centre de r&#xe9;f&#xe9;rence des maladies autoimmunes syst&#xe9;miques rares du nord et Nord-Ouest de France (CeRAINO), U1167 RID-AGE, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Guern</LastName><ForeName>V&#xe9;ronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Service de M&#xe9;decine Interne et d'Immunologie Clinique, Centre de r&#xe9;f&#xe9;rence des maladies autoimmunes syst&#xe9;miques rares du nord et Nord-Ouest de France (CeRAINO), U1167 RID-AGE, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paule</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hachulla</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Univ. Lille, Inserm, CHU Lille, Service de M&#xe9;decine Interne et d'Immunologie Clinique, Centre de r&#xe9;f&#xe9;rence des maladies autoimmunes syst&#xe9;miques rares du nord et Nord-Ouest de France (CeRAINO), U1167 RID-AGE, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mouthon</LastName><ForeName>Luc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupr&#xe9;</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ackermann</LastName><ForeName>F&#xe9;lix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, Foch Hospital, Referral Center for Hypereosinophilic Syndromes, Suresnes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dufrost</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Vascular Medicine Division and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, CHRU Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahl</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Vascular Medicine Division and Regional Competence Centre for Rare Vascular and Systemic Autoimmune Diseases, CHRU Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Godeau</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, Mondor Hospital, Paris France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leroux</LastName><ForeName>Ga&#xeb;lle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, AP-HP, La Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Referral Center for Rare Autoimmune and Systemic Diseases, Paris, France; and Sorbonne University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benhamou</LastName><ForeName>Ygal</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, Centre Hospitalier de Rouen, Rouen, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazaro</LastName><ForeName>Estibaliz</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, Centre Hospitalier de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daugas</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Nephrology, AP-HP, Bichat Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezanahary</LastName><ForeName>Holy</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, Centre Hospitalier Universitaire de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mekinian</LastName><ForeName>Ars&#xe8;ne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, APHP, Saint Antoine Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piette</LastName><ForeName>Jean-Charles</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Clinical Immunology, AP-HP, La Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Referral Center for Rare Autoimmune and Systemic Diseases, Paris, France; and Sorbonne University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morel</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costedoat-Chalumeau</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Internal Medicine Department, AP-HP, Referral Center for Rare Autoimmune and Systemic Diseases of Ile de France, Cochin Hospital, Paris, France; Universit&#xe9; Paris Cit&#xe9;, Center for Epidemiology and Statistics, Institut national de la sant&#xe9; et de la recherche m&#xe9;dicale, French National Institute for Agricultural Research, Paris, France. Electronic address: nathalie.costedoat@aphp.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Thromb Haemost</MedlineTA><NlmUniqueID>101170508</NlmUniqueID><ISSNLinking>1538-7836</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016736" MajorTopicYN="Y">Antiphospholipid Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015985" MajorTopicYN="N">Precipitating Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anticoagulant</Keyword><Keyword MajorTopicYN="N">antiphospholipid antibodies</Keyword><Keyword MajorTopicYN="N">antiphospholipid syndrome</Keyword><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">catastrophic antiphospholipid syndrome</Keyword></KeywordList><CoiStatement>Declaration of competing interests There are no competing interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>19</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36792010</ArticleId><ArticleId IdType="doi">10.1016/j.jtha.2023.02.007</ArticleId><ArticleId IdType="pii">S1538-7836(23)00146-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>